Document is current
Any future updates will be listed below
-
Authors
Izzo, Franco
Lee, Stanley C. https://orcid.org/0000-0001-7110-2416
Poran, Asaf
Chaligne, Ronan https://orcid.org/0000-0003-4332-3291
Gaiti, Federico https://orcid.org/0000-0001-5111-8816
Gross, Baptiste
Murali, Rekha R.
Deochand, Sunil D.
Ang, Chelston
Jones, Philippa Wyndham
Nam, Anna S.
Kim, Kyu-Tae
Kothen-Hill, Steven
Schulman, Rafael C.
Ki, Michelle
Lhoumaud, Priscillia
Skok, Jane A. https://orcid.org/0000-0002-4145-1516
Viny, Aaron D. https://orcid.org/0000-0001-7039-0110
Levine, Ross L.
Kenigsberg, Ephraim
Abdel-Wahab, Omar https://orcid.org/0000-0002-3907-6171
Landau, Dan A. https://orcid.org/0000-0003-2346-9541
-
Funding
Funding for this research was provided by:
Burroughs Wellcome Fund
Pershing Square Foundation
Foundation for the National Institutes of Health (DP2-CA239065)
EIF | Stand Up To Cancer (SU2C-AACR-IRG-0616)
American Society of Hematology
Marie Skłodowska-Curie
National Cancer Center
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI R00 CA218896, K08 CA215317)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (1R35GM122515)
Damon Runyon Cancer Research Foundation (DRG 117-15)
Edward P. Evans Foundation
Leukemia and Lymphoma Society
U.S. Department of Health & Human Services | National Institutes of Health (P30 CA008748)
- License Information
-
More Information
Article History
Received: 16 April 2019
Accepted: 19 February 2020
First Online: 23 March 2020
Competing interests
: O.A.-W. has served as a consultant for H3B Biomedicine, Foundation Medicine Inc., Merck and Janssen, and is on the Scientific Advisory Board of Envisagenics Inc. O.A.-W. has received prior research funding from H3B Biomedicine unrelated to the current manuscript. R.L.L. is on the supervisory board of Qiagen and is a scientific advisor to Loxo (until 2/2019), Imago, C4 Therapeutics and Isoplexis, which each include an equity interest. He receives research support from and consulted for Celgene and Roche, he has received research support from Prelude Therapeutics and he has consulted for Lilly, Incyte, Novartis, Astellas, Morphosys and Janssen. He has received honoraria from Lilly and Amgen for invited lectures and from Gilead for grant reviews.
